Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological ...

The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched the first phase three clinical trial for an indigenous dengu...

An expert committee recommended continuation of phase-II clinical trial of Serum Institute of India's vaccine against dengue after successf...

Takeda Pharmaceuticals' dengue vaccine assumes significance since the first vaccine ever licensed for dengue, developed by French drugmaker...

Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase it...

According to the World Health Organization, dengue represents one of the 10 biggest global health threats and it is critical to have access...

Disease prevention is key to public health in both developing and the developed world and vaccines have the potential to improve the qualit...

The mosquito-borne disease can be controlled only by the participation of the community as a whole, not just by an individual or a group.

Asian countries spend an estimated $6.5 billion annually in both direct and indirect medical costs due to dengue.

If cleared, the step may eventually pave the way for Dengvaxia's availability via the wide government distribution system and private chann...

The injection can thwart all four types of the virus, which has appeared in Portugal, France, Florida and Japan recently, according to WHO.

Shantha Biotech’s bread-winner vaccine has fallen out of favour with the World Health Organisation.

The government is expected to upgrade the existing three-in-once vaccine for infants to a five-in-one by the end of the year under the nati...

For a change, the bottomline and the bottom rung match up. India’s emerging pharma frat knows how to cash in low and cash out to grow-they ...